Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Cancer

Volumn 118, Issue 10, 2012, Pages 2594-2602

  Mittendorf, Elizabeth A ^a   Clifton, Guy T ^b   Holmes, Jarrod P ^c   Clive, Kevin S ^b   Patil, Ritesh ^d,e   Benavides, Linda C ^b   Gates, Jeremy D ^b   Sears, Alan K ^b   Stojadinovic, Alexander ^f   Ponniah, Sathibalan ^g   Peoples, George E ^b,g  

^a UNIVERSITY OF TEXAS   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^d Joyce Murtha Breast Cancer Center   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f WALTER REED ARMY MEDICAL CENTER   (United States)

^g Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

breast cancer; cancer vaccines; E75; HER2 neu; immunotherapy

Indexed keywords

CANCER VACCINE; E 75; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; ONCOGENE NEU; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CANCER VACCINES; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A2 ANTIGEN; HLA-A3 ANTIGEN; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; RISK; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84860700518     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26574     Document Type: Article

References (17)

1. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE,. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother. 2008; 57: 1511-1521.
2. Peoples GE, Holmes JP, Hueman MT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2008; 14: 797-803.
3. Holmes JP, Clifton GT, Patil R, et al. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2011; 117: 463-471.
4. Peoples GE, Gurney JM, Hueman MT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol. 2005; 23: 7536-7545.
5. Benavides LC, Gates JD, Carmichael MG, et al. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2009; 15: 2895-2904.
6. Holmes JP, Gates JD, Benavides LC, et al. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2008; 113: 1666-1675.
7. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684.
8. Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res. 2002; 8: 3394-3400.
9. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE,. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol. 2006; 13: 1085-1098.
10. zum Buschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H,. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 2002; 62: 2244-2247.
11. Amin A, Benavides LC, Holmes JP, et al. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol Immunother. 2008; 57: 1817-1825.
12. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
13. Campbell HE, Gray AM, Harris AL, Briggs AH, Taylor MA,. Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. Br J Cancer. 2010; 103: 776-786.
14. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005; 23: 619-629.
15. Klade CS, Wedemeyer H, Berg T, et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology. 2008; 134: 1385-1395.
16. Knutson KL, Schiffman K, Cheever MA, Disis ML,. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res. 2002; 8: 1014-1018.
17. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of 2 multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res. 2007; 13: 6386-6395.